Added to YB: 2025-04-24
Pitch date: 2025-04-22
NVCT [bullish]
Nuvectis Pharma, Inc.
-21.3%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology.
Market Cap
$154.2M
Pitch Price
$9.72
Price Target
N/A
Dividend
N/A
EV/EBITDA
N/A
P/E
-4.43
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Show full summary:
Tailwinds Yeehee - Nuvectis Pharma, Inc.
NVCT: NXP900 targets cancer by inhibiting SRC/YES1 pathways crucial in lung cancer mutations. First human results due April 29 at AACR 25. Potential FDA fast-track benefit for life-threatening conditions could accelerate approval timeline.
Read full article (1 min)